USA flag logo/image

An Official Website of the United States Government

THE OBJECTIVE OF THIS PROJECT IS TO DEVELOP A VACCINE DELIVERY SYSTEM WHICH…

Award Information

Agency:
Department of Defense
Branch:
Army
Award ID:
4330
Program Year/Program:
1986 / SBIR
Agency Tracking Number:
4330
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Ribi Immunochem Research, Inc.
553 OLD CORVALLIS RD Hamilton, MO 59840
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1986
Title: THE OBJECTIVE OF THIS PROJECT IS TO DEVELOP A VACCINE DELIVERY SYSTEM WHICH WILL STIMULATE, RAPIDLY, A STATE OF NON-SPECIFIC PROTECTION WHILE IT ENHANCES THE SPECIFIC IMMUNE RESPONSE TO THE VACCINE AND SHORTENS THE INDUCTION PERIOD FOR DEVELOPMENT OF
Agency / Branch: DOD / ARMY
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE OBJECTIVE OF THIS PROJECT IS TO DEVELOP A VACCINE DELIVERY SYSTEM WHICH WILL STIMULATE, RAPIDLY, A STATE OF NON-SPECIFIC PROTECTION WHILE IT ENHANCES THE SPECIFIC IMMUNE RESPONSE TO THE VACCINE AND SHORTENS THE INDUCTION PERIOD FOR DEVELOPMENT OF SPECIFIC IMMUNITY. THIS WILL BE ACCOMPLISHED BY PREPARING THE VACCINE IN AN OILIN-WATER EMULSION THAT CONTAINS NON-TOXIC IMMUNOSTIMULATORS OF MICROBIAL ORIGIN. BOTH SPECIFIC AND NON-SPECIFIC PROTECTION WILL BE TESTED AGAINST A MURINE MODEL OF INFLUENZA VIRUS INFECTION. THE HUMORAL ANTIBODY RESPONSES OF THE MICE WILL ALSO BE FOLLOWED TO ASSESS THE EFFECTIVENESS OF THE DELIVERY SYSTEM. EXPERIMENTAL REGIMENS WILL BE ESTABLISHED TO MEASURE THE CAPACITY OF THE DELIVERY VEHICLE ALONE, WITHOUT THE SPECIFIC VACCINE, TO PROTECT MICE NONSPECIFICALLY AGAINST AN AEROSOL CHALLENGE OF INFLUENZA VIRUS. THE KINETICS OF THE DEVELOPMENT OF THIS PROTECTION AS WELL AS THOSE FOR THE DEVELOPMENT OF SPECIFIC IMMUNITY WILL ALSO BE ASSESSED. FINALLY, A COMPARISON WILL BE MADE BETWEEN THE MINIMAL AMOUNT OF VACCINE, WITH AND WITHOUT IMMUNOSTIMULATORS, REQUIRED TO ENGENDER SPECIFIC PROTECTION. IT IS ANTICIPATED THAT DATA FROM THESE EXPERIMENTS WILL PROVIDE A FOUNDATION AND A RATIONALE FOR AN EXPANDED PHASE II PROJECT WHICH WILL INCLUDE CLINICAL TRIALS OF THESE AMMUNOSTIMULATORS IN HUMANS.

Principal Investigator:

J terry ulrich
4063636214

Business Contact:

Small Business Information at Submission:

Ribi Immunochem Research Inc
Po Box 1409 Hamilton, MT 59840

EIN/Tax ID:
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No